Anavex Life Sciences (AVXL) EBIT Growth (1y) (2017 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 12.69% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 75.16% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -347.04% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 80.62% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 1.27% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 8.65% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1,386.07% |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | 58.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 58.34% |
| Sep 30, 2025 | 24.01% |
| Jun 30, 2025 | 0.99% |
| Mar 31, 2025 | 0.88% |
| Dec 31, 2024 | -19.46% |
| Sep 30, 2024 | -12.73% |
| Jun 30, 2024 | -7.92% |
| Mar 31, 2024 | 11.04% |
| Dec 31, 2023 | 26.04% |
| Sep 30, 2023 | 17.18% |
| Jun 30, 2023 | -8.61% |
| Mar 31, 2023 | -23.18% |
| Dec 31, 2022 | -31.22% |
| Sep 30, 2022 | -32.03% |
| Jun 30, 2022 | -22.85% |
| Mar 31, 2022 | -41.73% |
| Dec 31, 2021 | -50.38% |
| Sep 30, 2021 | -94.34% |
| Jun 30, 2021 | -56.46% |
| Mar 31, 2021 | -12.32% |
| Dec 31, 2020 | -18.43% |
| Sep 30, 2020 | -6.36% |
| Jun 30, 2020 | 0.32% |
| Mar 31, 2020 | -0.53% |
| Dec 31, 2019 | 4.75% |
| Sep 30, 2019 | -0.78% |
| Jun 30, 2019 | -128.23% |
| Mar 31, 2019 | -52.38% |
| Dec 31, 2018 | -70.65% |
| Sep 30, 2018 | -8.00% |
| Jun 30, 2018 | 20.86% |
| Mar 31, 2018 | -206.87% |
| Dec 31, 2017 | -29.98% |
| Sep 30, 2017 | 20.90% |
| Jun 30, 2017 | -61.13% |